Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab versus nivolumab monotherapy in previously untreated advanced renal cell carcinoma
2023-508264-29-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Nivolumab plus ipilimumab with Nivolumab monotherapy (2 arms). Primary endpoints: Progression-free survival by BICR and Overall response rate by BICR. Planned start Jan 2024; status: authorised.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-508264-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508264-29-00.